Affiliation:
1. Institute of Process Engineering in Life Sciences—Section IV: Biomolecular Separation Engineering, Karlsruhe Institute of Technology (KIT), 76131 Karlsruhe, Germany
Abstract
Effective process development towards intensified processing for gene delivery applications using Hepatitis B core Antigen (HBcAg) virus-like particles (VLPs) relies on analytical methods for the absolute quantification of HBcAg VLP proteins and bound nucleic acids. We investigated a silica spin column (SC)-based extraction procedure, including proteinase K lysis and silica chromatography, for the absolute quantification of different species of nucleic acids bound to HBcAg VLPs analyzed by dye-based fluorescence assays. This revealed load-dependent nucleic acid recoveries of the silica-SC-based extraction. We also developed a reversed-phase high-performance liquid chromatography (RP-HPLC) method to separate and quantify the HBcAg proteins and the bound nucleic acids simultaneously without prior sample treatment by dissociation reagents. The method demonstrated sufficient linearity, accuracy, and precision coefficients and is suited for determining absolute protein and nucleic acid concentrations and HBcAg protein purities at various purification stages. Both the silica-SC-based extraction and the RP-based extraction presented overcome the limitations of analytical techniques, which are restricted to relative or qualitative analyses for HBcAg VLPs with bound nucleic acids. In combination with existing analytics, the methods for an absolute quantification of HBcAg VLPs and bound nucleic acids presented here are required to evaluate downstream purification steps, such as the removal of host cell-derived nucleic acids, concurrent protein loss, and efficient loading with therapeutic nucleic acids. Hence, the methods are key for effective process development when using HBcAg VLP as potential gene delivery vehicles.
Funder
the Deutsche Forschungsgemeinschaft (DFG) within the framework of SPP 1934
Subject
Virology,Infectious Diseases
Reference40 articles.
1. Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery;Rohovie;Bioeng. Transl. Med.,2017
2. He, J., Yu, L., Lin, X., Liu, X., Zhang, Y., Yang, F., and Deng, W. (2022). Virus-like Particles as Nanocarriers for Intracellular Delivery of Biomolecules and Compounds. Viruses, 14.
3. Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer;Jinming;Int. J. Cancer,2013
4. Nooraei, S., Bahrulolum, H., Hoseini, Z.S., Katalani, C., Hajizade, A., Easton, A.J., and Ahmadian, G. (2021). Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J. Nanobiotechnol., 19.
5. Engineering Virus-like Particles for Antigen and Drug Delivery;Hill;Curr. Protein Pept. Sci.,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献